Literature DB >> 16222736

Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.

Bayasi Guleng1, Keisuke Tateishi, Fumihiko Kanai, Amarsanaa Jazag, Miki Ohta, Yoshinari Asaoka, Hideaki Ijichi, Yasuo Tanaka, Jun Imamura, Tsuneo Ikenoue, Yasushi Fukushima, Keita Morikane, Makoto Miyagishi, Kazunari Taira, Takao Kawabe, Masao Omata.   

Abstract

AIM: Vascular endothelial growth factor (VEGF) is a potent mediator of peritoneal fluid accumulation following tumor progression. This study investigated the role of VEGF secreted by cancerous cells in the formation of malignant ascites.
METHODS: VEGF expression was eliminated by knockdown in the pancreas cancer cell-line PancO2 using vector-based short-hairpin type RNA interference (RNAi). Malignant ascites formation in the mouse was analyzed by intraperitoneal injection of PancO2 cells expressing VEGF or with expression knockdown.
RESULTS: The VEGF knockdown PancO2 cell was successfully established. Knockdown of VEGF did not affect cancer cell proliferation in vitro or in vivo. The volume of ascites following peritoneal expansion of the tumor in VEGF knockdown cells and control cells did not differ statistically in this in vivo study. Moreover, the VEGF concentration in the ascites did not differ statistically.
CONCLUSION: Malignant ascites formation might be mediated by VEGF production in noncancerous tissues, such as stromal compartments. An anti-VEGF strategy against malignant ascites could be applied to various tumors regardless of whether they secrete VEGF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222736      PMCID: PMC4320353          DOI: 10.3748/wjg.v11.i35.5455

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells.

Authors:  Makoto Miyagishi; Kazunari Taira
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

2.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

3.  Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts.

Authors:  H Pilch; K Schlenger; E Steiner; P Brockerhoff; P Knapstein; P Vaupel
Journal:  Int J Gynecol Cancer       Date:  2001 Mar-Apr       Impact factor: 3.437

4.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

5.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

6.  Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.

Authors:  Alicia Viloria-Petit; Lucile Miquerol; Joanne L Yu; Marina Gertsenstein; Capucine Sheehan; Linda May; Jack Henkin; Corrinne Lobe; Andras Nagy; Robert S Kerbel; Janusz Rak
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

7.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Authors:  Dorina Belotti; Paola Paganoni; Luigi Manenti; Angela Garofalo; Sergio Marchini; Giulia Taraboletti; Raffaella Giavazzi
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

10.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Authors:  K T Yeo; H H Wang; J A Nagy; T M Sioussat; S R Ledbetter; A J Hoogewerf; Y Zhou; E M Masse; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

View more
  2 in total

1.  Mindin is upregulated during colitis and may activate NF-kappaB in a TLR-9 mediated manner.

Authors:  Bayasi Guleng; Ya-Mei Lian; Jian-Lin Ren
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

2.  HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression.

Authors:  Yun-Peng Liu; Xiao-Ning Yang; Amarsanaa Jazag; Jin-Shui Pan; Tian-Hui Hu; Jing-Jing Liu; Bayasi Guleng; Jian-Lin Ren
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.